Global Cancer Immunotherapy Market Size, Share, Opportunities, And Trends By Type (Monoclonal antibodies (MABs), Checkpoint Inhibitors, Cytokines, Cancer vaccines, Adoptive Cell transfer), By Application (Skin cancer, Lung cancer, Leukemias, Bladder cancer, Others), And By Geography - Forecasts From 2023 To 2028

The global cancer immunotherapy market is projected to expand at a CAGR of 12.98% over the forecast period. Cancer immunotherapy is a treatment where the human body makes use of its natural defense mechanism also known as the immune system in order to identify, attack and kill cancer cells. There are many companies working in collaboration for designing drugs for cancer immunotherapy. Adopting unhealthy living conditions and the prevalence of cancer are driving the growth of the global cancer immunotherapy market. 

For boosting the immune system certain therapies are used, for example, the BCG therapy which is injected directly into the bladder and is found effective in about 70 percent of patients with early-stage bladder cancer. Other therapies include cytokines, radioimmunotherapy, and oncolytic virus therapy.

The National Cancer Institute of the U.S. Department of Health and Human Services is at the forefront of developing immunotherapies and is also working towards the understanding of the unknown mechanisms in immune responses against a specific cancer type and specific patient.

One of the NCI-funded research has led to the identification of biomarkers that can help in determining the type of patients more likely to respond to checkpoint inhibitor therapy. The biomarkers are PD-L1 and a genetic feature called microsatellite instability. Hence, it will become easier to detect patients who have these biomarkers and will respond to certain checkpoint inhibitors in comparison to patients lacking these biomarkers.

The cancer immunotherapy market is growing and will continue to grow in the Asia Pacific region due to the growing patient pool in the country accompanied by the growing cancer awareness, technological advancements, and growing demand from emerging economies like India and China. While North America is expected to show a major market share owing to the adoption of early innovations and the presence of key market players in this region followed by Europe.

Major industry players profiled as part of the report are Bristol-Myers Squibb Company, Eisai Co., Ltd., Nektar, and Servier among others.

Segmentation:

The global cancer immunotherapy market has been analyzed through the following segments:

• By Type

• Monoclonal antibodies (MABs)
• Checkpoint Inhibitors
• Cytokines
• Cancer vaccines
• Adoptive Cell transfer

 

• By Application

• Skin cancer
• Lung cancer
• Leukemias
• Bladder cancer
• Others

 

• By Geography

• North America

• United States
• Canada
• Mexico
• Others

 

• South America

• Brazil
• Argentina
• Others

 

• Europe

• Germany
• France
• Italy
• United Kingdom
• Others

 

• Middle East and Africa

• Israel
• Saudi Arabia
• UAE
• Others

 

• Asia Pacific

• Japan
• China
• India
• Australia
• South Korea
• Others

Servier

Sanofi

Xencor

Jounce Therapeutics, Inc.

Pfizer Inc.

Cellectis SA

CytomX Therapeutics, Inc.

Bristol-Myers Squibb Company

Nektar

Eisai Co., Ltd.